ADA SCID gene therapy - Orchard Therapeutics

Drug Profile

ADA SCID gene therapy - Orchard Therapeutics

Alternative Names: ADA gene therapy - Orchard Therapeutics; Adenosine deaminase gene therapy - Orchard Therapeutics; Autologous cryopreserved EFS-ADA LV CD34 cells; Autologous ex-vivo lentiviral adenosine deaminase gene therapy - Orchard Therapeutics; OTL-101

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orchard Therapeutics
  • Developer Great Ormond Street Hospital; Orchard Therapeutics; University of California at Los Angeles
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Adenosine deaminase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenosine deaminase deficiency
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Adenosine deaminase deficiency

Most Recent Events

  • 24 Apr 2018 Orchard announces intention to submit BLA to US FDA for Adenosine deaminase deficiency in 2018, with potential commercialisation in 2018
  • 22 Aug 2017 The UK MHRA designates Promising Innovative Medicine designation to ADA-SCID gene therapy for Adenosine deaminase deficiency in the United Kingdom
  • 24 Jul 2017 ADA SCID gene therapy - Orchard Therapeutics receives Breakthrough Therapy status for Adenosine deaminase deficiency in USA before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top